Biologics CDMO, Northway Biotech, Expands To The US: Boston Facility Grand Opening

There is little doubt that biologics have transformed modern medicine in the treatment of many diseases and conditions - positively changing many people's futures. Biologics have revolutionized cancer treatment, reversed the course of immune related conditions, and offered new hope for patients with rare genetic conditions. As many biologics developers utilize CDMOs to augment their existing supply or use CDMOs for portions or all development and manufacturing needs – choosing the right outsourcing partner can be overwhelming. 

Outsourcing challenges are multifaceted and often the result of balancing equally important needs such as cost, timelines, and quality. Finding the right CDMO capacity, capabilities, and cost balance can be difficult leaving many questions still to be answered. What is the experience level of the staff? Are timelines met consistently? How strong is their regulatory team and track record? Equally challenging is finding a CDMO with the right people and cultural fit where the CDMO and sponsor teams can cooperate, communicate well, and ultimately work towards a common goal together. These questions and challenges are critical to address in assessing how a CDMO partner will likely perform on your project and with your people. 

Biopharmaceutical companies rely on their trusted CDMO partners to help navigate the intricate journey through clinical and commercial drug development. What if it were possible to get a closer look into the people and the facility entrusted with your life-changing biologic?  

Northway Biotech invites you to take a glimpse into their CDMO world and welcomes you (virtually) to share a grand opening experience. Hear from Massachusetts Life Science Leaders, meet the Northway team and learn more about this remarkable new facility designed to help biopharmaceutical companies navigate the full biologic drug development lifecycle.

Speakers include:

• Vladas Algirdas Bumelis, CEO and Chairman of the Board | Northway Biotech
• Michael J. Barrett, MA State Senator | Commonwealth of Massachusetts
• Ben Bradford, VP of Membership and Economic Development | MassBio
• Jeannette A. McCarthy, Mayor of Waltham, Massachusetts
• Janice M. Reichert, Executive Director | The Antibody Society
• Thomas Stanley, MA State Representative | Commonwealth of Massachusetts
• Mark F. Sullivan, Executive Director | Massachusetts Office of International Trade & Investment
• Kenneth L. Turner, President and CEO | Massachusetts Life Sciences Center

About Northway Biotech

Northway Biotech is an end-to-end biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant state-of-the-art cGMP manufacturing site in Europe and the United States. Northway Biotech’s new site located in the booming Boston Area biotech hub has been supporting both local and international customers with biologics process, analytical method development and manufacturing since Summer 2020.